N/A N=4,732 Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Breast Cancer
Primary: Disease-free Survival — 5.44; 5.45 DFS events/100*person-year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=298 Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Ovarian · Breast · Prostate
Primary: Tumour Response Rate — 12.9; 31.1; 21.7; 50 Percentage of participants
N/A N=1 Prostate Cancer Screening in Men With Germline BRCA2 Mutations
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Phase 2 N=91 Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
Phase 2 N=33 Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer
Breast Adenocarcinoma · Deleterious BRCA1 Gene Mutation · Deleterious BRCA2 Gene Mutation
Primary: Number of Participants With Overall Pathological Complete Response (pCR) — 7; 10; 3; 2 Participants
Phase 2 N=63 ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
Phase 2 N=74 A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours
Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants
Phase 2 N=111 A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Phase 2 N=9 Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Phase 3 N=513 A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.6; 14.6 months — p=0.003
Phase 2 N=21 Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Phase 3 N=255 To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
HER2-ve Metastatic Breast Cancer · Germline BRCA1/2 Mutations · Somatic BRCA1/2 Mutations
Primary: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants — 8.18 months
Phase 4 N=202 Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
Ovarian Cancer · Breast Cancer
Primary: Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and…
Phase 3 N=302 Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) — 7.0…
Phase 3 N=431 A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Breast Neoplasms · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment — 8.6; 5.6 months — p=<0.0001
Phase 2 N=88 Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
HER2-negative Breast Cancer
Primary: Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC) — 38.2; 61.9 Percentage of participants — p=0.0210
Phase 2 N=14 Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR) Per RECIST1.1 — 7 Participants
Phase 2 N=294 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.3; 14.1; 7.4 months — p=0.227
Phase 2 N=135 PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
N/A N=33 Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Metastatic Breast Cancer · Breast Neoplasms
Primary: Time to Treatment Failure (TTF) for Talazoparib — 5.5 Months
Phase 3 N=266 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Phase 2 N=11 Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
Advanced Breast Cancer
Primary: Overall Response Rate (ORR) — 1 Participants
Phase 2 N=14 Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma
Primary: Proportion of Patients With PSA Decline by 50% From Baseline — 9; 5 Participants
Phase 2 N=54 Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
Breast Neoplasms
Primary: Confirmed Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 25.0; 42.3 Percentage of participants
N/A N=84 Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Time to Treatment Failure (TTF) for Talazoparib — 8.5 Months
Phase 1 N=21 Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer
Neoplasms, Breast
Primary: Percentage of Participants With Tumor Response Measured by Breast MRI — 90.5 Percentage of participants
Phase 2 N=124 Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Phase 2 N=37 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Mesothelioma · Uveal Melanoma · Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 5.6; 0 percentage of subjects
Phase 2 N=118 Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
Breast Cancer
Primary: Rate of Pathologic Complete Response (pCR) — 0; 0 Participants
Phase 2 N=40 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
BRCA1 Gene Mutation · BRCA2 Gene Mutation · Ovarian Serous Adenocarcinoma
Primary: Incidence of Dose-limiting Toxicities (DLTs) Defined as the Rate of Drug-related Grade 3-5 Adverse Events Assessed Using the National Cancer Institute Common Terminology…